For lung cancer patients in India, the treatment chair has been a fixed point — hours of intravenous drip, hospital waits, repeated travel for each cycle. A new injection shifts that equation. On June 9, Roche Pharma India launched Tecentriq SC, a subcutaneous formulation of the immunotherapy drug atezolizumab. It takes about seven minutes to administer.
That is a radical compression. Standard intravenous infusion of the same drug can run thirty minutes to an hour, not counting preparation and post-infusion observation. The company says Tecentriq SC can treat up to five patients in the time it takes to treat one by IV. For a country where lung cancer incidence is rising and hospital infrastructure is unevenly distributed, that math matters.
The drug itself is not new. Atezolizumab, marketed as Tecentriq, has been used intravenously for years against non-small cell lung cancer and other solid tumors. It works by blocking PD-L1, a protein tumors use to hide from the immune system. What is new is the delivery. The subcutaneous version uses a formulation that allows a larger dose to be injected under the skin in a fraction of the time.
Patient preference data backs the shift. Results from the IMscin002 study, presented at the European Lung Cancer Congress, showed four out of five patients preferred the subcutaneous injection over IV administration. The reasons are not hard to guess. Less time in a hospital chair. No need for a vein to be cannulated each time. Fewer trips for caregivers who often take time off work to accompany a patient.
Roche framed the launch around reducing indirect treatment costs. For a patient who lives far from a major cancer center, every hour saved in the hospital can mean a return trip the same day instead of an overnight stay. For the hospital, faster turnover of infusion chairs means more patients can be treated. The company’s statement described the potential to “dramatically improve the cancer treatment experience.” That is a deliberately broad claim, but the numbers give it weight.
Lung cancer remains the most common cancer in India among men and a leading cause of cancer death overall. Most cases are diagnosed late. Treatment is expensive, prolonged, and physically draining. Any change that cuts time without cutting efficacy is a meaningful step. The subcutaneous formulation was approved by the U.S. Food and Drug Administration in September 2024 and has since rolled out in multiple countries. India is now part of that rollout.
Roche did not disclose pricing for the Indian market. Cost will determine real-world adoption. Tecentriq IV is already covered under some corporate insurance policies and patient assistance programs. Whether the subcutaneous version follows the same path is an open question. But the clinical logic is straightforward: faster administration, same drug, same mechanism.
The launch also signals a broader trend in oncology — shifting complex biologics from infusion centers to simpler settings. Subcutaneous formulations of trastuzumab and rituximab already exist. Atezolizumab joins that list. For patients, the difference is not abstract. Seven minutes versus an hour. One needle stick versus a drip. A treatment that fits into a morning rather than consuming a day.
That is the change Roche is betting on. The company cited ongoing research into further applications of atezolizumab SC across other cancer types. For now, the immediate effect is for lung cancer patients in India who have few options and less time to spend on them.
